Prefilled Syringes & Injection Devices101
Issue No #101 Oct 2019 October 2nd, 2019
Inside the magazine
Michael McGowan, Director of Market Intelligence at SHL Group, gives a perspective on the emergence of the autoinjector as a key component of the drug delivery industry, in the context of SHL celebrating its 30th anniversary this year – a journey of rapid development that reflects the growing demand for advanced drug delivery systems in the healthcare market.
Fred Metzmann reports on the latest state-of-the-art developments in innovative injection devices for combination products in subcutaneous self-application. He outlines Haselmeier's product platform strategy for single-use (D-Flex) and re-usable (i-pen²) injection-pen systems, and related services and looks at the company’s connected digital solutions.
Napoleon Monroe asks why connectivity has failed to advance rapidly, and argues that many stakeholders can benefit if the adoption of connectivity for drug delivery can be accelerated. While this article will centre on pharmaceutical combination products, the essential points also relate more broadly to pharmaceuticals and medical devices.
David Fink and Stefan Gaul use the example of Haselmeier’s D-Flex system to explain why it is important to undertake a full use-related risk analysis for injection pen products to assess their usability and identify any risks, highlighting the importance of considering usability right from the start.
In the context of the growing shift in emphasis from improving adherence to the better outcomes that can arise from doing so, Iain Simpson discusses why connectivity is becoming increasingly important in injectable drug delivery, and how it can benefit patients, providers and pharmaceutical manufacturers.